



July 21, 2022

To The Manager Listing Department National Stock Exchange of India Limited 'Exchange Plaza', C - 1, Block G, Bandra-Kurla Complex, <u>Bandra (E), Mumbai 400051.</u> Scrip Code: INDOCO	To BSE Limited Corporate Relationship Department 1 st Floor, New Trading Ring, Phiroze Jeejeebhoy Towers Dalal Street <u>Mumbai 400001</u> Scrip Code : 532612
---	---

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015-
USFDA successfully concludes inspection at Anacipher CRO- Hyderabad**

In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you the successful conclusion of the USFDA inspection at Indoco's Clinical Research Organization - AnaCipher, conducted between 11th - 15th July, 2022.

During the remote record review, the agency did not identify any objectionable conditions and thus, did not have any observations. This inspection was conducted by the Division of New Drug Study Integrity, Office of Study Integrity and Surveillance of USFDA. The scope of the inspection included Bioanalytical phase of multiple studies, of which one was "First to File".

The above is for your information and records.

Thanking you,

**Yours faithfully,
For Indoco Remedies Limited**


Jayshankar Menon
Company Secretary & AVP - Legal



INDOCO REMEDIES LIMITED

Indoco House, 166, C.S.T. Road, Kalina, Santacruz (E), Mumbai 400098, India.
Tel. No.: +91 22 6287 1000 / 6879 1250 ■ CIN: L85190MH1947PLC005913

www.indoco.com